Abstract：
UNASSIGNED: An accurate assessment of tumor viability after first-line treatment is critical for predicting treatment failure in peripheral T-cell lymphomas (PTCLs). 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has been adopted as the preferred assessment method in clinical trials, but its impact in clinical practice should be examined. This study aims to determine the prognostic significance of18F-FDG-PET/CT for survival following first-line treatment in PTCL patients.
UNASSIGNED: Retrospective observational study including 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites.
UNASSIGNED: Fifty patients were evaluated with18F-FDG-PET/CT following first-line therapy: 58% were18F-FDG-PET/CT-negative and 42% were18F-FDG-PET/CT-positive. Disease progression occurred in 37.9% of18F-FDG-PET/CT-negative patients and in 80.9% of18F-FDG-PET/CT-positive patients (p = 0.0037). Median progression-free survival and overall survival were 67 and 74 months for18F-FDG-PET/CT-negative patients, and 5 (p < 0.0001) and 10 months (p < 0.0001), respectively, in18F-FDG-PET/CT-positive patients. After multivariate analysis, only B symptoms emerged as a negative predictive factor of complete response (RR 7.08; 95% CI 1.60-31.31; p = 0.001).
UNASSIGNED: 18F-FDG-PET/CT identifies high-risk PTCL patients who will have poor prognosis and survival following first-line treatment. However, more research is needed to confirm the best treatment options for PTCL patients.
UNASSIGNED: Retrospective observational study including 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites.
UNASSIGNED: Fifty patients were evaluated with18F-FDG-PET/CT following first-line therapy: 58% were18F-FDG-PET/CT-negative and 42% were18F-FDG-PET/CT-positive. Disease progression occurred in 37.9% of18F-FDG-PET/CT-negative patients and in 80.9% of18F-FDG-PET/CT-positive patients (p = 0.0037). Median progression-free survival and overall survival were 67 and 74 months for18F-FDG-PET/CT-negative patients, and 5 (p < 0.0001) and 10 months (p < 0.0001), respectively, in18F-FDG-PET/CT-positive patients. After multivariate analysis, only B symptoms emerged as a negative predictive factor of complete response (RR 7.08; 95% CI 1.60-31.31; p = 0.001).
UNASSIGNED: 18F-FDG-PET/CT identifies high-risk PTCL patients who will have poor prognosis and survival following first-line treatment. However, more research is needed to confirm the best treatment options for PTCL patients.
摘要：
■一线治疗后肿瘤活力的准确评估对于预测外周T细胞淋巴瘤（PTCL）的治疗失败至关重要。18F-氟代脱氧葡萄糖（18F-FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）已被用作临床试验的首选评估方法，但它在临床实践中的影响应该被检查。本研究旨在确定18F-FDG-PET/CT对PTCL患者一线治疗后生存的预后意义。
■回顾性观察研究，包括2008-2013年间在西班牙13个地点诊断为PTCL的175名患者。
■在一线治疗后对50例患者进行了18F-FDG-PET/CT评估：58％为18F-FDG-PET/CT阴性，42％为18F-FDG-PET/CT阳性。疾病进展发生在37.9%的18F-FDG-PET/CT阴性患者和80.9%的18F-FDG-PET/CT阳性患者中(p=0.0037)。18F-FDG-PET/CT阴性患者的中位无进展生存期和总生存期分别为67和74个月。5(p<0.0001)和10个月(p<0.0001)，分别,18F-FDG-PET/CT阳性患者。经过多变量分析，只有B症状作为完全缓解的阴性预测因素出现(RR7.08;95%CI1.60-31.31;p=0.001).
■18F-FDG-PET/CT可识别一线治疗后预后和生存不良的高危PTCL患者。然而,需要更多的研究来确认PTCL患者的最佳治疗方案.
■回顾性观察研究，包括2008-2013年间在西班牙13个地点诊断为PTCL的175名患者。
■在一线治疗后对50例患者进行了18F-FDG-PET/CT评估：58％为18F-FDG-PET/CT阴性，42％为18F-FDG-PET/CT阳性。疾病进展发生在37.9%的18F-FDG-PET/CT阴性患者和80.9%的18F-FDG-PET/CT阳性患者中(p=0.0037)。18F-FDG-PET/CT阴性患者的中位无进展生存期和总生存期分别为67和74个月。5(p<0.0001)和10个月(p<0.0001)，分别,18F-FDG-PET/CT阳性患者。经过多变量分析，只有B症状作为完全缓解的阴性预测因素出现(RR7.08;95%CI1.60-31.31;p=0.001).
■18F-FDG-PET/CT可识别一线治疗后预后和生存不良的高危PTCL患者。然而,需要更多的研究来确认PTCL患者的最佳治疗方案.
